Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) Targeting Tumor-Specific Neoantigens, With in Vivo CD40 Activation and PD-1 Blockade, for Patients With Incurable Cancers (2020000584)

Next Previous
X
Search
Trial Profile

Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) Targeting Tumor-Specific Neoantigens, With in Vivo CD40 Activation and PD-1 Blockade, for Patients With Incurable Cancers (2020000584)

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CDX 1140 (Primary) ; Pembrolizumab (Primary) ; TCR-transduced lymphocytes (Primary) ; Cyclophosphamide; Epirubicin; Gemcitabine
  • Indications Cancer; Carcinoma; Glandular and epithelial neoplasms
  • Focus Adverse reactions

    • Most Recent Events

    • 28 Jul 2023 Status changed from recruiting to active, no longer recruiting.
    • 09 Feb 2022 Planned End Date changed from 31 Jan 2027 to 28 Feb 2027.
    • 09 Feb 2022 Planned primary completion date changed from 31 Jan 2025 to 28 Feb 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top